David Fallace
InvestorManaging Partner at Cure Ventures · Board director at RYNE Biotechnology Inc.
Massachusetts
Writes $100K – $5M checks · typically $1.5M
About
Managing Partner and Co-Founder of Cure Ventures with over 20 years investing in venture and alternative asset funds. Previously advised Polaris Partners and held roles at TIFF Investment Management, the Alaska Permanent Fund and GF Private Equity Group.
Contact· self-published, not guessed
Board director at RYNE Biotechnology Inc.
Intro paths
→
In turn, David can intro founders to RYNE Biotechnology Inc.'s investors below.
RYNE Biotechnology Inc.'s investors · 2
Experience
- Cure VenturesManaging Partner and Co-foundercurrent2021 — presentBoston, Massachusetts, United States
- Polaris PartnersAdviser2018 — 2019Boston, Massachusetts
- The Investment Fund for FoundationsManaging Director2016 — 2017Greater Boston
- Codiak BiosciencesInvestor2015 — 2016Greater Boston
- Denali TherapeuticsBoard Observer2015 — 2016San Francisco Bay Area
- Alaska Permanent Fund CorporationDirector - Special Opportunities2013 — 2016Juneau, Alaska
- Juno TherapeuticsBoard Observer2013 — 2014Greater Seattle Area
- Haugen Financial SystemsVice President2009 — 2013
- GF Private Equity GroupVice President2000 — 2009
Skills & more
Private Equity50Portfolio Management35Hedge Funds25Real Estate10Alternative Investments27Venture Capital43Asset Management16Asset Allocation1Corporate Development1Derivatives1Asset Managment3Emerging Markets1
From David's professional profile.
Deals · 1
RYNE Biotechnology Inc.Board seat
via Cure Ventures · filed Mar 2024 · $81.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Per SEC Form D filings.
Colleagues at Cure Ventures
Albert J. Robichaud
Partner at Cure Ventures
Annie Mitsak
Partner at Cure Ventures
Bill Amsbaugh
CTO and Partner at Cure Ventures
Courtney Turner
Director of Finance at Cure Ventures
Dr. Michael Aberman
Investor at Cure Ventures
Dr. Milenko Cicmil
Investor at Cure Ventures
Drew King
CFO and Partner at Cure Ventures
James Vath
Partner at Cure Ventures
Network5
Bill Amsbaugh
CTO and Partner at Cure Ventures
Drew King
CFO and Partner at Cure Ventures
James Vath
Partner at Cure Ventures
Kenzie MacIsaac
Partner at Cure Ventures
May Han
Partner at Cure Ventures
Investors connected to David in public investor directories — a warm-intro map.
Frequently asked questions
- Who is David Fallace?
- Managing Partner and Co-Founder of Cure Ventures with over 20 years investing in venture and alternative asset funds. Previously advised Polaris Partners and held roles at TIFF Investment Management, the Alaska Permanent Fund and GF Private Equity Group.
- Where does David Fallace work?
- David Fallace is Managing Partner at Cure Ventures and Board director at RYNE Biotechnology Inc..
- What check size does David Fallace write?
- David Fallace typically writes checks of $100K – $5M.
- What boards does David Fallace sit on?
- David Fallace holds tracked board seats at RYNE Biotechnology Inc., Tasca Therapeutics.
- Where did David Fallace go to school?
- David Fallace studied at University at Buffalo School of Management, The State University of New York (MBA, Finance); University at Buffalo School of Law (Juris Doctor, Tax and Financial Transactions).
Same school
Also attended University at Buffalo School of Management, The State University of New York18
Sam AckermanAssistant Controller at Declaration PartnersKevin McAdamsSenior Analyst at Declaration PartnersJamie RiegerVice President at Declaration PartnersJoshua GilbertInvestor at TMV LogisticsJoanne LeeSenior Associate at NetroveFouad AzzamPartner at EQT Life Sciences
+ 12 more
Also attended University at Buffalo School of Law2
Shared employers
Also worked at Polaris Partners43
Dylan PearcePartner at GreycroftGraham BrownManaging Partner at Lerer HippeauMichael GreeleyCo-Founder and General Partner at Flare Capital PartnersSimeon SimeonovAdvisor at One Way VenturesPaige LimOffice Manager at Square Peg CapitalKirti AnandFund Controller at Polaris Partners
+ 37 more
Also worked at The Investment Fund for Foundations3
Also worked at Denali Therapeutics3
Also worked at Alaska Permanent Fund Corporation8
Deven MitchellExecutive Director & CEO at Alaska Permanent Fund CorporationMarcus FramptonChief Investment Officer at Alaska Permanent Fund CorporationValerie MertzChief Financial Officer at Alaska Permanent Fund CorporationRoss AlexanderSenior Portfolio Manager — Private Income at Alaska Permanent Fund CorporationValeria MartinezDirector of Total Fund Cash at Alaska Permanent Fund CorporationScott BalovichDirector of IT at Alaska Permanent Fund Corporation
+ 2 more